Comprehensive Assessment of Metabolic Enzyme and Transporter Genes Using the Affymetrix^® Targeted Genotyping System

• Lewis DF : Human P450s in the metabolism of drugs: molecular modelling of enzyme-substrate interactions.Expert Opin. Drug Metab. Toxicol.1(1) , 5–8 (2005).
   PubMedGoogle Scholar
• Choudhuri S , KlaassenCD: Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP) and ABCG2 (BCRP) efflux transporters.Int. J. Toxicol.25(4) , 231–259 (2006).
   PubMed Web of Science ®Google Scholar
• Ishikawa T , TsujiA, InuiK et al.: The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics5(1) , 67–99 (2004).
   PubMed Web of Science ®Google Scholar
• Werck-Reichhart D , FeyereisenR: Cytochromes P450: a success story.Genome Biol.1(6) , REVIEWS3003 (2000).
   PubMedGoogle Scholar
• Cascorbi I : Genetic basis of toxic reactions to drugs and chemicals.Toxicol. Lett.162(1) , 16–28 (2006).
   PubMed Web of Science ®Google Scholar
• Gemignani F , LandiS, VivantF et al.: A catalogue of polymorphisms related to xenobiotic metabolism and cancer susceptibility. Pharmacogenetics12(6) , 459–463 (2002).
   PubMedGoogle Scholar
• Liebler DC , GuengerichFP: Elucidating mechanisms of drug-induced toxicity.Nat. Rev. Drug Discov.4(5) , 410–420 (2005).
   PubMed Web of Science ®Google Scholar
• Sakurai A , TamuraA, OnishiY, IshikawaT: Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications.Expert Opin. Pharmacother.6(14) , 2455–2473 (2005).
   PubMed Web of Science ®Google Scholar
• Evans WE , McLeodHL: Pharmacogenomics – drug disposition, drug targets, and side effects.N. Engl. J. Med.348(6) , 538–549 (2003).
   PubMed Web of Science ®Google Scholar
• Dervieux T , MeshkinB, NeriB: Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications.Mutat. Res.573(1–2) , 180–194 (2005).
   PubMed Web of Science ®Google Scholar
• Bonnet-Brilhault F , BrolyF, BlancR et al.: An ADHD 6-year-old child ultrarapid metabolizer for CYP2D6. J. Clin. Psychopharmacol.26(4) , 442–444 (2006).
   PubMed Web of Science ®Google Scholar
• Eichelbaum M , KroemerHK, MikusG: Genetically determined differences in drug metabolism as a risk factor in drug toxicity.Toxicol. Lett.64–65 Spec No, 115–122 (1992).
   Web of Science ®Google Scholar
• Furuta T , ShiraiN, SugimotoM et al.: Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab. Pharmacokinet.20(3) , 153–167 (2005).
   PubMedGoogle Scholar
• Johnson M , Markham-AbediC, SusceMT et al.: A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment. CNS Spectr.11(10) , 757–760 (2006).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J , HenckelHB, FrankeL et al.: Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet. Genomics15(8) , 579–587 (2005).
   PubMed Web of Science ®Google Scholar
• Zanger UM , RaimundoS, EichelbaumM: Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.Naunyn Schmiedebergs Arch. Pharmacol.369(1) , 23–37 (2004).
   PubMed Web of Science ®Google Scholar
• Shah RR : Can pharmacogenetics help rescue drugs withdrawn from the market?Pharmacogenomics7(6) , 889–908 (2006).
   PubMed Web of Science ®Google Scholar
• Monro AM : Why do so many drugs fail between the laboratory and the marketplace? In: The Use of Human in vitro System to Support Preclinical and Clinical Safety Assessment. Sundwall A, Alván G, Lindgren E, Moldéus P, Salmonsson T, Sjöberg P (Eds), Swedish Association of the Pharmaceutical Industry and Medical Products Agency, Stockholm, Sweden, 1–4 (1996).
   Google Scholar
• Gut IG : Automation in genotyping of single nucleotide polymorphisms.Hum. Mutat.17(6) , 475–492 (2001).
   PubMed Web of Science ®Google Scholar
• Kristensen VN , KelefiotisD, KristensenT, Borresen-DaleAL: High-throughput methods for detection of genetic variation.Biotechniques30(2) , 318–326 (2001).
   PubMed Web of Science ®Google Scholar
• Kwok PY : Methods for genotyping single nucleotide polymorphisms.Annu. Rev. Genomics Hum. Genet.2 , 235–258 (2001).
   PubMed Web of Science ®Google Scholar
• Kwok PY : High-throughput genotyping assay approaches.Pharmacogenomics1(1) , 95–100 (2000).
   PubMedGoogle Scholar
• Shi MM : Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies.Clin. Chem.47(2) , 164–172 (2001).
   PubMed Web of Science ®Google Scholar
• Tsuchihashi Z , DracopoliNC: Progress in high throughput SNP genotyping methods.Pharmacogenomics J.2(2) , 103–110 (2002).
   PubMedGoogle Scholar
• Jenkins S , GibsonN: High-throughput SNP genotyping.Comp. Funct. Genomics3 , 57–66 (2002).
   PubMed Web of Science ®Google Scholar
• Ragoussis J , ElvidgeGP, KaurK, ColellaS: Matrix-assisted laser desorption/ionisation, time-of-flight mass spectrometry in genomics research.PLoS Genet.2(7) , e100 (2006).
   PubMed Web of Science ®Google Scholar
• de la Vega FM , LazarukKD, RhodesMD, WenzMH: Assessment of two flexible and compatible SNP genotyping platforms: TaqMan SNP Genotyping Assays and the SNPlex Genotyping System.Mutat. Res.573(1–2) , 111–135 (2005).
   PubMed Web of Science ®Google Scholar
• Tobler AR , ShortS, AndersenMR et al.: The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. J. Biomol. Tech.16(4) , 398–406 (2005).
   PubMedGoogle Scholar
• Dunbar SA : Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection.Clin. Chim. Acta363(1–2) , 71–82 (2006).
   PubMed Web of Science ®Google Scholar
• Kokoris M , DixK, MoynihanK et al.: High-throughput SNP genotyping with the Masscode system. Mol. Diagn.5(4) , 329–340 (2000).
   PubMedGoogle Scholar
• Macdonald SJ , PastinenT, GenisselA, CornforthTW, LongAD: A low-cost open-source SNP genotyping platform for association mapping applications.Genome Biol.6(12) , R105 (2005).
   PubMed Web of Science ®Google Scholar
• Shen R , FanJB, CampbellD et al.: High-throughput SNP genotyping on universal bead arrays. Mutat. Res.573(1–2) , 70–82 (2005).
   PubMed Web of Science ®Google Scholar
• Bell PA , ChaturvediS, GelfandCA et al.: SNPstream UHT: ultra-high throughput SNP genotyping for pharmacogenomics and drug discovery. Biotechniques Suppl. 70–2, 74 , 76–77 (2002).
   Web of Science ®Google Scholar
• Pastinen T , RaitioM, LindroosK et al.: A system for specific, high-throughput genotyping by allele-specific primer extension on microarrays. Genome Res.10(7) , 1031–1042 (2000).
   PubMed Web of Science ®Google Scholar
• Hardenbol P , BanerJ, JainM et al.: Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat. Biotechnol.21(6) , 673–678 (2003).
   PubMed Web of Science ®Google Scholar
• Hardenbol P , YuF, BelmontJ et al.: Highly multiplexed molecular inversion probe genotyping: over 10.000 targeted SNPs genotyped in a single tube assay. Genome Res.15(2) , 269–275 (2005).
   PubMed Web of Science ®Google Scholar
• Moorhead M , HardenbolP, SiddiquiF et al.: Optimal genotype determination in highly multiplexed SNP data. Eur. J. Hum. Genet.14(2) , 207–215 (2006).
   PubMed Web of Science ®Google Scholar
• ParAllele Bioscience, Inc.: TrueCall™ Analyzer Software User Guide, Rev. 4.0.ParAllele BioScience, Inc. (now a part of Affymetrix, Inc., [CA, USA]) 2–7 (2005).
   Google Scholar
• The International HapMap Consortium: A haplotype map of the human genome. Nature437(7063) , 1299–1320 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor AL , ZiescheS, YancyC et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med.351(20) , 2049–2057 (2004).
   PubMed Web of Science ®Google Scholar
• Hiratsuka M , InoueT, OmoriF, Agatsuma Y, Mizugaki M: Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population. Mutat. Res.448(1) , 91–95 (2000).
   PubMed Web of Science ®Google Scholar
• Relling MV , HancockML, RiveraGK et al.: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst.91(23) , 2001–2008 (1999).
   PubMedGoogle Scholar
• Herman D , LocatelliI, GrabnarI et al.: Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J.5(3) , 193–202 (2005).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J , BrockmollerJ: Clinical consequences of cytochrome P450 2C9 polymorphisms.Clin. Pharmacol. Ther.77(1) , 1–16 (2005).
   PubMed Web of Science ®Google Scholar
• Peyvandi F , SpreaficoM, SiboniSM, Moia M, Mannucci PM: CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin. Pharmacol. Ther.75(3) , 198–203 (2004).
   PubMed Web of Science ®Google Scholar
• Ando Y , HasegawaY: Clinical pharmacogenetics of irinotecan (CPT-11).Drug Metab. Rev.37(3) , 565–574 (2005).
   PubMed Web of Science ®Google Scholar
• Ando Y , UeokaH, SugiyamaT et al.: Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther. Drug Monit.24(1) , 111–116 (2002).
   PubMed Web of Science ®Google Scholar
• O’Dwyer PJ , CatalanoRB: Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.J. Clin. Oncol.24(28) , 4534–4538 (2006).
   PubMed Web of Science ®Google Scholar

Websites

• Human Cytochrome P450 Allele Nomenclature Committee www.cypalleles.ki.se/
   Google Scholar
• National Centre for Biotechnology Information single nucleotide polymorphism database www.ncbi.nlm.nih.gov/projects/SNP/
   Google Scholar
• The Pharmacogenetics and Pharmacogenomics Knowledge Base www.pharmgkb.org/index.jsp
   Google Scholar
• Roche Diagnostics AmpliChip® information www.amplichip.us/?gclid=CNvPgrX1zogCFQFISQod1DFrCg
   Google Scholar
• Third Wave Technologies, Inc. www.twt.com
   Google Scholar